- Home
- GBDC vs AXSM Comparison
GBDC vs AXSM Comparison
Compare GBDC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBDC | AXSM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 7.4B |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GBDC | AXSM |
|---|---|---|
| Price | $13.48 | $153.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 20 |
| Target Price | $14.83 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 1.6M | 479.4K |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | ★ 11.89% | N/A |
| EPS Growth | ★ 4.09 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $870,777,000.00 | $561,263,000.00 |
| Revenue This Year | N/A | $66.20 |
| Revenue Next Year | N/A | $57.56 |
| P/E Ratio | $9.51 | ★ N/A |
| Revenue Growth | 20.16 | ★ 65.83 |
| 52 Week Low | $12.68 | $75.56 |
| 52 Week High | $16.01 | $154.49 |
Technical Indicators
Market Signals| Indicator | GBDC | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.61 | 64.08 |
| Support Level | $13.53 | $145.07 |
| Resistance Level | $13.74 | $149.13 |
| Average True Range (ATR) | 0.17 | 4.48 |
| MACD | -0.08 | -0.35 |
| Stochastic Oscillator | 7.73 | 94.96 |
Price Performance
Historical ComparisonAbout GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.